VJHemOnc is committed to improving our service to you

BSH 2018 | Novel agents for sickle cell disease

VJHemOnc is committed to improving our service to you

Bart Biemond

Speaking from the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Bart Biemond, MD, PhD, from the Academic Medical Centre, Amsterdam, Netherlands, discusses new therapeutic approaches in sickle cell disease that are targeting red blood cell adhesion and oxygen affinity, both of which drive most of the organ failure seen in latter stages of the disease. Examples of these drugs include rivipansel, crizanlizumab and modified heparin agents that are currently in Phase II or III trials

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter